The U.S. Food and Drug Administration has approved a significantly higher-dose version of the weight-loss medication Wegovy, providing a new option for adults seeking greater average weight reduction. The newly approved 7.2 mg dose of semaglutide, to be marketed as Wegovy HD, triples the previous maximum available strength.
The approval, granted to Novo Nordisk, was supported by clinical trial data demonstrating enhanced efficacy. In the pivotal study, patients using the higher dose achieved an average weight loss of 20.7% of their body weight. This compares to an average loss of about 16% for those on the standard 2.4 mg dose. The agency stated the new dose is indicated to reduce excess body weight and maintain that reduction long-term for adults with obesity or those who are overweight with at least one weight-related condition.
Jamey Millar, executive vice president of US operations for Novo Nordisk, said the company is excited to offer what he called a powerful weight-loss medicine, noting that Wegovy has also been shown to reduce the risk of major cardiovascular events in people with heart disease. For patients with both obesity and type 2 diabetes, the higher dose showed similar blood sugar-lowering effects compared to the lower dose. However, independent specialist Dr. Peter Balazs emphasized that this approval is specifically for obesity management, not diabetes treatment, and that current semaglutide dosing for diabetes remains lower unless weight loss is the primary goal.
The safety profile for the higher dose is consistent with the known effects of semaglutide, though some side effects were more pronounced. Common gastrointestinal reactions like nausea and diarrhea are expected. The FDA reported that skin sensitivity, pain, or burning occurred more frequently with the higher dose but generally resolved on their own or with a dose reduction. The agency also reiterated warnings that the drug should not be used by patients with a personal or family history of certain thyroid cancers or a rare endocrine syndrome.
Looking ahead, this approval provides a new, evidence-based path for patients who may plateau on the standard dose or who have a very high starting body mass index. While Dr. Balazs views the higher dose as a "major jump" that allows Novo Nordisk to remain competitive, he does not expect it to dramatically reshape the broader GLP-1 medication landscape, noting that next-generation therapies with different mechanisms are in development. The introduction of Wegovy HD represents an incremental but significant advance, offering clinicians and patients a stronger tool within the established semaglutide treatment framework for long-term weight management.